Is 256U87 hydrochloride Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 256U87 hydrochloride? Is 256U87 hydrochloride safe for nursing mother and child? Does 256U87 hydrochloride extracts into breast milk? Does 256U87 hydrochloride has any long term or short term side effects on infants? Can 256U87 hydrochloride influence milk supply or can 256U87 hydrochloride decrease milk supply in lactating mothers?

Precursor of Aciclovir which is used for treatment of infections due to Herpes zoster and Herpes simplex viruses and the prevention of Cytomegalovirus infection in immunocompromised patients. It is excreted into breast milk as Aciclovir in non-significant clinical amount, with no side-effects observed among breastfed infants from treated mothers. Urine levels of Aciclovir in those infants were shown to be very low.

The dosage of acyclovir in milk after 256U87 hydrochloride is less than 1% of a typical infant dosage and would not be expected to cause any adverse effects in breastfed infants. No special precautions are required when using 256U87 hydrochloride during breastfeeding. In one study, administration of 256U87 hydrochloride to mothers with concurrent herpes simplex type 2 and HIV infections reduced breastmilk shedding of the HIV virus in breastmilk at 6 and 14 weeks postpartum, but not later.[1] In another study in HIV-positive mothers, 256U87 hydrochloride did not reduced breastmilk shedding of cytomegalovirus (CMV) or infant CMV acquisition.[2]

In a study of pregnant women with concurrent HIV and Herpes simplex infections, mothers received zidovudine 300 mg daily from week of pregnancy until 12 months postpartum and nevirapine at delivery. Half of the women (n = 74) also received 256U87 hydrochloride 500 mg orally twice daily from 34 weeks gestation until 12 months postpartum. At 6 weeks postpartum, all infants who received acyclovir in breastmilk had normal serum creatinine (<0.83 mg/dL). Their median serum creatinine and alanine aminotransferase (ALT) values, and growth were no different from those of unexposed infants, with the exception of one infant with an ALT level of 70.1 units/L. Infants whose mothers received 256U87 hydrochloride generally had adverse effects that were similar to the placebo group, except that treated infants had a lower risk of eczema and oral thrush than infants in the placebo arm.[1][4]